HAPPENING NOW
Health · 1 views
GLP-1 shows promise for patients with advanced fatty liver disease
Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial…
AI Summary
Researchers at the University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage c…
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Health
Continue reading recent Health coverage
- Semaglutide and other GLP-1 drugs not linked to risk of degenerative eye disease in adults with type 2 diabetesContinue reading
- Wildfire smoke is like smoking 'half a pack a day.' Here's how to protect yourselfContinue reading
- Cyclosporiasis outbreak traced to lettuce from Mexico used by Taco BellContinue reading